Test Price
2,800 AED✅ Home Collection Available
PYCR1 Gene Sequencing Test for Cutis Laxa Type 2B in UAE
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139) utilizing Next-Generation Sequencing (NGS).
- ✓ Premium Logistics: Paid, Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy service (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Mandatory pre-test genetic counselling session and telephonic post-test clinical guidance for result interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This advanced molecular genetic test analyzes the PYCR1 gene using Next-Generation Sequencing (NGS) to confirm a molecular diagnosis of Autosomal Recessive Cutis Laxa Type 2B (ARCL2B), a severe connective tissue disorder characterized by progeroid features, joint laxity, and developmental delay. Our validated protocol provides the definitive genetic blueprint essential for multidisciplinary management, surpassing the limitations of symptomatic dermatological evaluation and enabling proactive surveillance for life-threatening complications such as aortic root dilatation and osteopenia.
| Feature | DNA Labs UAE Platform | Standard Alternative |
|---|---|---|
| Precision | Full gene coverage with CNV analysis via NGS | Single-gene Sanger sequencing only |
| Methodology | LC-MS/MS validated library preparation & bioinformatics pipeline | Standard PCR-based screening |
| Diagnostic Speed | 3 to 4 Weeks with comprehensive clinical report | Often 6-8 weeks or non-diagnostic |
Physician Insight & Safety Protocols
"As a Consultant in Medical Genetics, I must emphasize that a molecular diagnosis of PYCR1-related cutis laxa is a lifelong journey requiring coordinated, multi-systemic care. This genetic test result is the critical first map, not the final destination. Our team stands by to guide the interpretation, integrating genomic data with the patient's unique clinical presentation. I urge families to view this result as a powerful tool for proactive surveillance, from osteology to cardiology, rather than a definitive sentence."
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Pre-Test Advisory & Medication Safety
Do not discontinue any prescribed medication or supplement without explicit consultation with your managing physician. The sample type (Whole Blood, Extracted DNA, or FTA Card) does not exempt the patient from the mandatory pre-test genetic counselling session required for informed consent.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent or complete a clinical pedigree chart.
- Exclusion: Recent hematopoietic stem cell transplant (may require alternative sample type).
- Exclusion: Active systemic infection unmanaged prior to blood draw (consult physician).
- ER Red Flag: If the patient exhibits acute neurological regression, intractable seizures, or severe respiratory distress, seek emergency care immediately; do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. What does the PYCR1 gene NGS test definitively diagnose, and why is molecular confirmation critical for my child's health?
This NGS test definitively identifies pathogenic mutations in the PYCR1 gene to confirm Autosomal Recessive Cutis Laxa Type 2B, a condition impacting the skin, skeleton, and brain. Because the clinical presentation mimics other progeroid syndromes, a precise molecular diagnosis is the only way to initiate targeted surveillance for life-threatening complications like aortic root dilatation or severe osteopenia, moving care from observation to proactive, multidisciplinary management.
2. Why is a mandatory genetic counselling session required before providing a blood sample?
The mandatory pre-test genetic counselling session ensures fully informed consent and constructs a three-generation pedigree chart to map the autosomal recessive inheritance pattern. This clinical context is critical for our bioinformatics team to accurately distinguish rare benign family variants from truly disease-causing mutations, ensuring the highest standard of diagnostic accuracy in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
3. What is the expected turnaround time for the clinical report, and how does early diagnosis impact patient outcomes?
The expected turnaround time is 3 to 4 Weeks from sample receipt in the laboratory. This duration is necessary to ensure robust analytical depth and clinical accuracy. Early molecular diagnosis of PYCR1 deficiency is crucial as it enables proactive monitoring for structural, neurological, and metabolic complications, allowing for early therapeutic interventions that significantly improve long-term quality of life and survival outcomes.
UAE Regulatory & Data Privacy Adherence
Your Data, Secured by UAE Law
- Data Protection: We strictly adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all genomic and medical records.
- Health Information Governance: Our laboratory information management system (LIMS) complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: All procedures, including genetic testing and patient consent protocols, are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Accreditation: Our processes are ISO 9001:2015 accredited (Cert: INT/EGQ/2509DA/3139), ensuring rigorous quality management and data integrity.
Clinical & Logistical Metadata
| Test Name | PYCR1 Gene Sequencing Test (Cutis Laxa Type 2B, Autosomal Recessive) |
| Price (AED) | 2800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) with Full Gene Coverage & CNV Analysis |
| ICD-10-CM Code | Q82.8 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians